Jefferies keeps Buy rating for GSK stock ahead of results

Published on 10/20/2026 at 10:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK revenue reached GBP 8.41 billion in its second quarter. GSK stock costs EUR 22.09 on October 20, 2026, 0.41 percent above Xetra close.

Upcoming results shape the setup

Jefferies maintained its Buy rating for GSK on October 19, 2026.
Second-quarter revenue reached GBP 8.41 billion versus GBP 7.99 billion a year earlier.
GSK stock traded at EUR 22.09 at 10:31 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.41 percent above the Xetra close of October 19, 2026.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK (ISIN GB00BN7SWP63) was trading at EUR 22.09 at Lang & Schwarz on October 20, 2026, 0.41 percent above the Xetra close of October 19, 2026 at EUR 22.00. Markets Insider reported on October 19, 2026 that Jefferies maintained its Buy rating for GSK and kept a price target of GBP 25.00.

Three dates shape GSK expectations

On July 28, 2026, GSK reported second-quarter revenue of GBP 8.41 billion, up from GBP 7.99 billion a year earlier, while net profit was GBP 435 million versus GBP 1.44 billion. On October 13, 2026, RBC maintained a Sector Perform rating and a GBp 1,975 target ahead of the results. On October 19, 2026, Jefferies maintained its Buy rating while the latest quarter's revenue figure remained GBP 8.41 billion.

What does RBC expect from results?

According to Yahoo Finance on October 13, 2026, RBC forecast third-quarter revenue of GBP 8.82 billion against consensus of GBP 8.89 billion. RBC also forecast core earnings per share of GBp 50.80, matching consensus, while Nucala revenue was projected at GBP 623 million, 7.00 percent above consensus.

When are the next catalysts?

Yahoo Finance reported that GSK is scheduled to publish third-quarter results on October 28, 2026. The same report identified a regulatory decision on bepirovirsen on October 26, 2026 and an oncology investor update on October 27, 2026 as near-term events.

Stock stays near EUR 22.00

The current euro quotation places the stock just above the prior Xetra session's closing level, while the upcoming report will test whether HIV and respiratory-medicine strength can offset pressure in vaccines. GSK's latest reported revenue comparison gives investors a concrete benchmark for that test. The further course of trading is shown by the continuously updated real-time quote of GSK stock.